Immune repertoire sequencing reveals differences in treatment response to camrelizumab plus platinum-based chemotherapy in advanced ESCC

This study evaluated the efficacy and safety of camrelizumab combined with platinum-based chemotherapy (taxanes [T] or fluorouracil agents [F] plus platinum [P] drugs) as the first-line treatment in advanced esophageal squamous cell carcinoma (ESCC), using immune repertoire sequencing (IRS) to explore treatment response mechanism. In this multi-center, prospective cohort study, 88 patients received camrelizumab plus TP or FP, achieving a 1-year progression-free survival of 56.8% and overall survival of 68.2%. The objective response rate (ORR) was 64.8%, with a disease control rate of 91.1%. While most treatment-related adverse events were mild, 12.5% of patients experienced grade ≥3 toxicities. IRS showed significant differences in T-cell receptor (TCR) b-chain and immunoglobulin heavy chain between patients with (ORR group) or without ORR (non-ORR group), particularly in the distribution and expression of some genes. Specifically, we found significant differences in the amino acid comp..., , , # Immune repertoire sequencing reveals differences in treatment response to camrelizumab plus platinum-based chemotherapy in advanced ESCC

[https://doi.org/10.5061/dryad.0cfxpnwcf](https://doi.org/10.5061/dryad.0cfxpnwcf)

## Description of the data and file structure

We collected clinical information from 88 patients and immune repertoire information from 30 patients.

We have provided R software analysis code for clinical data analysis.

### Files and variables

#### File: 88\_Dataset.xlsx

**Description:** We collected clinical information from 88 patients, including their tumor grade, ECOG performance status, cancer stage, tumor site, treatment group, treatment start and end dates, treatment duration (in days), number of immunotherapy cycles, number of combined immunotherapy and chemotherapy cycles, number of maintenance immunotherapy cycles, best efficacy evaluation, progression-free survival (PFS) status, progression time, PFS duration, overall survival (OS) status, OS time, OS ...